Last reviewed · How we verify
Risedronate (HMR4003)
Risedronate inhibits bone resorption by binding to hydroxyapatite on bone surfaces and inhibiting osteoclast activity.
Risedronate inhibits bone resorption by binding to hydroxyapatite on bone surfaces and inhibiting osteoclast activity. Used for Osteoporosis in postmenopausal women, Osteoporosis in men, Paget's disease of bone.
At a glance
| Generic name | Risedronate (HMR4003) |
|---|---|
| Sponsor | Sanofi |
| Drug class | Bisphosphonate |
| Target | Hydroxyapatite (bone mineral); osteoclast farnesyl pyrophosphate synthase |
| Modality | Small molecule |
| Therapeutic area | Bone metabolism / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
Risedronate is a bisphosphonate that localizes to sites of bone resorption and directly inhibits osteoclast function, reducing bone turnover. By suppressing osteoclast-mediated bone resorption, it increases bone mineral density and reduces fracture risk in conditions characterized by accelerated bone loss.
Approved indications
- Osteoporosis in postmenopausal women
- Osteoporosis in men
- Paget's disease of bone
- Glucocorticoid-induced osteoporosis
Common side effects
- Gastrointestinal irritation (esophageal irritation, dyspepsia, abdominal pain)
- Musculoskeletal pain (bone, joint, muscle pain)
- Headache
- Diarrhea
- Atypical femoral fracture (rare)
- Osteonecrosis of the jaw (rare)
Key clinical trials
- Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women (PHASE3)
- Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women (PHASE3)
- Risedronate in the Prevention of Osteoporosis in Postmenopausal Women (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Risedronate (HMR4003) CI brief — competitive landscape report
- Risedronate (HMR4003) updates RSS · CI watch RSS
- Sanofi portfolio CI